Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 986406263
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2018.10.10, AU 2018903820
2019.02.04, AU 2019900326
2019.09.24, AU 2019903556
GHOSH P et al.: "Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study", Curr Ther Res, vol. 66, no. 6, November 2005 (2005-11), pages 552-71, XP005303372, DOI: 10.1016/j.curtheres.2005.12.012 (B1)
HWANG P et al.: "Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis", Urology, vol. 50, no. 1, July 1997 (1997-07), pages 39-43, XP001036819, DOI: 10.1016/S0090-4295(97)00110-6 (B1)
Hsin-Tzu Liu ET AL: "Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment", BJU International, vol. 104, no. 10, 1 November 2009 (2009-11-01), pages 1476-1481, XP055701672, Hoboken, USA ISSN: 1464-4096, DOI: 10.1111/j.1464-410X.2009.08675.x (B1)
JIANG YH et al.: "Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid", PLoS One, vol. 9, no. 3, 10 March 2014 (2014-03-10), XP055701682, (B1)
KUMAR V et al.: "NGF- the tikA to successful pain treatment", J Pain Res, vol. 5, 2012, pages 279-87, XP055249637, (B1)
LIU HT et al.: "Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment", BJU Int, vol. 104, no. 10, November 2009 (2009-11), pages 1476-81, XP055701672, (B1)
VINAYAK KUMAR ET AL: "NGF – the TrkA to successful pain treatment", JOURNAL OF PAIN RESEARCH, 1 August 2012 (2012-08-01), page 279, XP055249637, DOI: 10.2147/JPR.S33408 (B1)
MCCAFFREY et al.: "NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use", Cancer Res., vol. 74, no. 23, 1 December 2014 (2014-12-01), pages 7014-23, XP055701677, (B1)
MCMAHON SB: "NGF as a mediator of inflammatory pain", Philos Trans R Soc Lond B Biol Sci, vol. 351, no. 1338, 29 March 1996 (1996-03-29), pages 431-40, XP000980634, (B1)
SAMPSON MJ et al.: "Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report", BMC Musculoskelet Disord, vol. 1 8, no. l, 12 September 2017 (2017-09-12), page 396, XP055572039, (B1)
SEVCIK M A ET AL: "Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 115, no. 1-2, 1 May 2005 (2005-05-01) , pages 128-141, XP004844690, ISSN: 0304-3959, DOI: 10.1016/J.PAIN.2005.02.022 (B1)
US-B2- 9 101 650 (B1)
MATTHEW J. SAMPSON ET AL: "Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report", BMC MUSCULOSKELETAL DISORDERS, vol. 18, no. 1, 12 September 2017 (2017-09-12), pages 1-5, XP055572039, DOI: 10.1186/s12891-017-1754-3 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3863647)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3863647)
|
Innkommende, AR611968450
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 6. avg. år (EP) | 2024.10.09 | 2600 | CPA GLOBAL LIMITED | Betalt og godkjent |
32405584 expand_more expand_less | 2024.04.24 | 7254 | PLOUGMANN VINGTOFT NUF | Betalt |
Valideringsgebyr EP-patent
7150 = 1 X 7150
Gebyr ved bruk av MasterCard-kort
104 = 104 X 1
|